Search company, investor...
Karmic Lifesciences company logo

Karmic Lifesciences

Founded Year



Acquired | Acquired

Total Raised


About Karmic Lifesciences

Karmic Lifesciences is an ISO 9001:2008, ISO 27001:2005 certified and ICH-GCP compliant, full-service Contract Research Organization headquartered in India with global execution capabilities in the US, Europe and APAC.

Headquarters Location

802, Bldg 3, Raheja Mindspace Thane Belapur Road Airoli, Navi, Maharastra

Mumbai, 400 708,


Missing: Karmic Lifesciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Karmic Lifesciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Karmic Lifesciences News

Cliantha Research Acquires VC Backed CRO Karmic Lifesciences

Jul 30, 2014

Mergers & Acquisitions | 30 July 2014 Cliantha Research Acquires VC Backed CRO Karmic Lifesciences by Tilak Devadiga   @Tilak Ahmedabad based global lifesciences company @Cliantha_Research Limited has acquired Mumbai headquartered contract research organization, Karmic Lifesciences for an undisclosed amount. The deal provides an exit to VC investors including @Mumbai_Angels , India Angel network, Basil Partners who had invested $2.5 Mn in equity funding over multiple rounds. With the buy Cliantha expands its presence in the clinical data management, pharmaceutical analytics and medical marketing business. Alternative Investment Market Advisors Private Limited was the sell side advisor. Karmic had raised $500,000 in its first round of funding from @Indian_Angel (IAN)in 2009. In the following year it bagged an investment of INR 30 Mn from Mumbai Angels and an undisclosed amount from Basil Global Corporation (Fund). Founded in 2005 by Nidhi Saxena, Karmic is an end to end solutions provider enabling the pharma companies to prove that the drug has primary efficacies, when the latter seeks to launch a new drug. It has developed kTrials™, a proprietary 21 CFR Part 11, CDASH/CDISC and SDTM Compliant, Web-Enabled eClinical Suite which supports end-to-end operational activities right from project set-up, planning, budgeting, execution, performance analytics and reporting for all clinical trials conducted by Karmic apart from storing all clinical and operational enterprise data as well as electronic trial master files in a single repository. The company claims to have a track record of executing 60+ Clinical Trials and 75+ Clinical Data Management & Bio-Statistics Projects (Phase I to IV) besides supporting Study Design, Medical & Scientific Writing for over 100 protocols across broad-based therapeutic areas including Oncology, Cardiovascular, Diabetes, Neurology, Auto-Immune Diseases, Ophthalmology, Medical Devices etc. It had touched INR 150 Mn in revenues in FY 13 and in FY14, it had planned to touch INR 560-600 Mn. Cliantha Research, is a global full service contract research organization with offerings in Clinical, Bioanalytical, Dermatology, Biometrics, Pathology and Formulation services. In 2011, Cliantha had acquired Hill Top Research, a global CRO in USA & Canada providing services in Phase I, Dermatology Rx and Personal Healthcare. Recent deals in this space: GVK BioSciences Private Limited, exercising its call option had acquired the balance 987,500 equity shares constituting 6.12% of voting powers of Inogent Laboratories from Dai-Ichi Karkaria Limited for a consideration of INR 89.7 Mn. SeQuent Scientific Limited had acquired the manufacturing assets and business of Mysore based Arvee Synthesis Private Limited. GVK Biosciences had acquired pre clinical CRO, Aragen Biosciences Inc for an undisclosed amount.

Karmic Lifesciences Frequently Asked Questions (FAQ)

  • When was Karmic Lifesciences founded?

    Karmic Lifesciences was founded in 2006.

  • Where is Karmic Lifesciences's headquarters?

    Karmic Lifesciences's headquarters is located at 802, Bldg 3, Raheja Mindspace Thane Belapur Road, Mumbai.

  • What is Karmic Lifesciences's latest funding round?

    Karmic Lifesciences's latest funding round is Acquired.

  • How much did Karmic Lifesciences raise?

    Karmic Lifesciences raised a total of $500K.

  • Who are the investors of Karmic Lifesciences?

    Investors of Karmic Lifesciences include Cliantha Research, Indian Angel Network and Excel Venture Management.

  • Who are Karmic Lifesciences's competitors?

    Competitors of Karmic Lifesciences include GenScript, Cognate BioServices, EyePoint Pharmaceuticals, ReaMetrix, Benten BioServices and 11 more.

Compare Karmic Lifesciences to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities.

Functional Biosciences

Functional Biosciences specializes in genomics research. The company produces reagents and an informatics tools, and aims to provide services that simplify preclinical drug development, reduce the costs of toxicity screening, improve the efficiency of DNA sequencing, and more.


GAAS Corporation aims to isolate and characterize anti-inflammatory components from turmeric, the rhizome of the plant Curcuma longa, and ultimately develop an effective and safe anti-inflammatory agent. Per the company, the oil fraction of turmeric has anti-inflammatory function, up to 30 times more effective than the supplements currently on the market and similar to that of indomethacin, a commercial OTC drug. GAAS Corporation also specializes in developing analytical methods and providing analytical services that are guaranteed to comply with current dietary supplement regulatory mandates and scientific standards. These analytical services include (i) contract analyses of individual samples and sets of samples for active ingredients and impurities, (ii) method developments for production testing, as well as (iii) design and implementation of quality control procedures.


Plymouth Marine Laboratory (PML) has been conducting research into marine organisms for more than 20 years funded by NERC. EcoAlert Ltd has been formed by PML's wholly owned technology transfer company, Plymouth Marine Applications Ltd (PMA), to commercialise a bioassay technique arising from this work. The Company has exclusive rights to ECOBOX, a portable bioassay kits for in-situ analysis of marine, estuarine and freshwater aquatic environments.


Plexigen is developing a 3-D biochip to enhance the capacity, efficiency, accuracy, and automation of gene screening. The technology was originally developed at North Carolina State University.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.